galantamine has been researched along with Nicotine Addiction in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brede, E; MacLean, RR; Sofuoglu, M; Waters, AJ | 1 |
| Liu, X | 1 |
| Blendy, JA; Hayes, MR; Hopkins, TJ; Rupprecht, LE; Schmidt, HD | 1 |
| Herman, AI; Li, Y; Sofuoglu, M; Waters, AJ | 1 |
| Batra, A; Croissant, B; Diehl, A; Mann, K; Nakovics, H; Smolka, MN | 1 |
3 trial(s) available for galantamine and Nicotine Addiction
| Article | Year |
|---|---|
Effects of galantamine on smoking behavior and cognitive performance in treatment-seeking smokers prior to a quit attempt.
Topics: Adult; Cholinesterase Inhibitors; Cognition; Cotinine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Galantamine; Humans; Male; Nootropic Agents; Patient Acceptance of Health Care; Patient Satisfaction; Smokers; Smoking; Smoking Cessation; Smoking Cessation Agents; Tobacco Use Disorder; Treatment Outcome | 2018 |
Galantamine attenuates some of the subjective effects of intravenous nicotine and improves performance on a Go No-Go task in abstinent cigarette smokers: a preliminary report.
Topics: Behavior, Addictive; Blood Pressure; Cholinesterase Inhibitors; Cognition; Connecticut; Cross-Over Studies; Double-Blind Method; Female; Galantamine; Heart Rate; Humans; Infusions, Intravenous; Logistic Models; Male; Neuropsychological Tests; Nicotine; Nicotinic Agonists; Pilot Projects; Severity of Illness Index; Smoking; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; Surveys and Questionnaires; Task Performance and Analysis; Time Factors; Tobacco Use Disorder | 2012 |
Galantamine reduces smoking in alcohol-dependent patients: a randomized, placebo-controlled trial.
Topics: Administration, Cutaneous; Adult; Alcoholism; Cholinesterase Inhibitors; Cotinine; Double-Blind Method; Female; Galantamine; Humans; Male; Middle Aged; Nicotine; Patient Compliance; Sex Factors; Skin Diseases; Smoking; Smoking Cessation; Smoking Prevention; Time Factors; Tobacco Use Disorder; Treatment Outcome | 2006 |
2 other study(ies) available for galantamine and Nicotine Addiction
| Article | Year |
|---|---|
Positive allosteric modulation of α4β2 nicotinic acetylcholine receptors as a new approach to smoking reduction: evidence from a rat model of nicotine self-administration.
Topics: Allosteric Regulation; Animals; Azetidines; Dose-Response Relationship, Drug; Galantamine; Hydrocarbons, Brominated; Indole Alkaloids; Male; Nicotine; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Reinforcement Schedule; Self Administration; Smoking Cessation; Smoking Prevention; Tobacco Use Disorder | 2013 |
Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats.
Topics: Allosteric Regulation; Animals; Cholinesterase Inhibitors; Drug-Seeking Behavior; Extinction, Psychological; Galantamine; Male; Nicotine; Rats; Receptors, Nicotinic; Smoking Cessation; Tobacco Use Disorder | 2012 |